CytomX Therapeutics Reports Positive Interim Phase 1 Data

CytomX Therapeutics ( (CTMX) ) has shared an update.

On May 12, 2025, CytomX Therapeutics announced positive interim Phase 1 data for its EpCAM PROBODY® ADC candidate, CX-2051, in advanced colorectal cancer. The data, as of April 7, 2025, showed a 28% overall response rate among efficacy-evaluable patients, with a 94% disease control rate and manageable adverse events. The company has commenced dose expansions and plans to initiate a Phase 2 study in the first half of 2026. CytomX ended the first quarter with $79.9 million in cash, extending its operational runway into the second quarter of 2026, and achieved a $5 million milestone payment from Astellas.

Spark’s Take on CTMX Stock

According to Spark, TipRanks’ AI Analyst, CTMX is a Neutral.

CytomX Therapeutics presents a mixed investment case. Strong revenue growth and positive technical momentum are encouraging, with a low P/E ratio suggesting potential undervaluation. However, significant risks stem from the negative equity position and cash flow challenges, which could impact long-term sustainability. The earnings call’s positive guidance, focusing on advancing clinical programs and strategic collaborations, offers some optimism, but the financial health concerns weigh on the overall outlook.

To see Spark’s full report on CTMX stock, click here.

More about CytomX Therapeutics

CytomX Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics designed to target the tumor microenvironment. Its pipeline includes antibody-drug conjugates, T-cell engagers, and immune modulators, with strategic collaborations with companies like Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna.

Average Trading Volume: 2,414,916

Technical Sentiment Signal: Sell

Current Market Cap: $74.85M

For a thorough assessment of CTMX stock, go to TipRanks’ Stock Analysis page.